China Research and Intelligence Market Research Reports

TITLE Actions
Investigation Report on China's Leuprorelin Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Leuprolide is a synthetic gonadotropin drug used to treat hormone-responsive cancers such as prostate cancer and breast cancer. It can also be used to treat precocious puberty and prevent premature ovulation during in vitro fertilization. Leuprolide ...

Investigation Report on China's Moxifloxacin Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Moxifloxacin is a fourth-generation synthetic quinolone antibacterial drug (8-methoxy-fluoroquinolone antibiotic) developed by Bayer Vital GmbH. It was approved for marketing by the FDA in December 1999. Moxifloxacin can be used to treat several infe...

Investigation Report on China's Acetylcysteine Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Acetylcysteine, also known as N-acetylcysteine (NAC), is a medication that is used to treat paracetamol (acetaminophen) overdose, and to loosen thick mucus in individuals with chronic bronchopulmonary disorders like pneumonia and bronchitis. Acetylcy...

Investigation Report on Global and China's MOSFET Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

MOSFET is an acronym for Metal Oxide Semiconductor Field Effect Transistor, also known as MOS, MOS transistor. The name "metal–oxide–semiconductor" (MOS) typically refers to a type of insulated-gate field-effect transistor that is fabricated by the c...

Investigation Report on China's Enteral Nutrition Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Enteral nutrition is mainly used for preoperative feeding of patients with anorexia and related diseases, including mechanical gastrointestinal dysfunction, critical illness and malnutrition. It was developed by Fresenius Kabi and was China in 1995. ...

Investigation Report on China's Insulin Glargine Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Insulin Glargine is a long-acting human insulin analog that can control the patient's blood sugar more effectively and steadily. It is often used to treat type 1 and type 2 diabetes. Its original research manufacturer is Sanofi, and its trade name is...

Investigation Report on China's Emtricitabine/Tenofovir Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Emtricitabine/Tenofovir is the first HIV drug approved for prophylaxis. It was developed by Gilead Sciences Inc (the original drug is called TRUVADA). Its product was first approved in the United States in 2004 and was launched in China in 2012. TRUV...

Investigation Report on China's Recombinant human thrombopoietin (rhTPO) Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Recombinant Human Thrombopoietin(rhTPO), developed by Shenyang Sansheng Pharmaceutical Co., Ltd., was approved for marketing in China in 2005 and used to treat thrombocytopenia caused by chemotherapy. It was approved for the treatment of immune throm...

Investigation Report on China's Express Delivery Industry 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Express delivery is a door-to-door logistics activity with postal functions, which means express companies use rail, road, and air transportation to quickly deliver customers' goods. According to CRI’s analysis, the efficiency and functi...

Investigation Report on China's Hydrotalcite Market, 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Hydrotalcite is suitable for acute and chronic gastritis, reflux esophagitis, gastric and duodenal ulcers, stomach pain, heartburn, acid belching, fullness and other uncomfortable symptoms related to gastric acid. It is also used to prevent gastric m...

Investigation Report on China's Goserelin Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Goserelin is a synthetic analogue of a naturally occurring gonadotropin-releasing hormone (GnRH). Goserelin is developed by AstraZeneca, is mainly used to treat advanced breast and prostate cancer. In 1996, 3.6 mg of Goserelin was approved to enter t...

Investigation Report on China's Levofloxacin Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Levofloxacin, developed by Daiichi Sankyo, is used to treat bacterial infectious diseases such as community pneumonia, sinusitis, urinary tract infections. Levofloxacin tablets were approved in China in 1995, and Levofloxacin injection and oral regul...

Investigation Report on China's Doxorubicin Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Doxorubicin belongs to the anthracycline class (Anthracycline) antibiotics, which can inhibit the synthesis of RNA and DNA. It has a strong inhibitory effect on RNA and has a broad anti-tumor spectrum. It has an effect on a variety of tumors. Doxorub...

Investigation Report on China's Dexmedetomidine Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Dexmedetomidine is a highly selective ?2-adrenergic receptor agonist. It is mainly used clinically for the sedation of tracheal intubation and mechanical ventilation in surgical patients undergoing general anesthesia. It was developed by Abbott and O...

Investigation Report on China's Anlotinib Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Anlotinib is an oral multi-targeting small-molecule tyrosine kinase inhibitor that can target multiple angiogenic factor receptors to inhibit tumor angiogenesis. It can be used for advanced non-small cell lung cancer (NSCLC), soft tissue sarcoma, cle...

Investigation Report on China's Rabeprazole Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Rabeprazole is a kind of proton pump inhibitor (PPI) gastric acid inhibitor. It is used for the treatment of gastroesophageal reflux disease and maintenance treatment after recovery. It is also suitable for the treatment of duodenal ulcers and Zollin...

Investigation Report on China's Ruxolitinib Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Ruxolitinib was developed by Novartis Pharma Schweiz AG. It is an orally bioavailable Janus-associated kinase (JAK) inhibitor with selectivity for subtypes JAK1 and JAK2. Its product is used for the treatment of medium and high-risk myelofibrosis in ...

Investigation Report on China's Omalizumab Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Omalizumab, developed by Novartis Europharm, is the only approved antibody designed to target and block immunoglobulin E (IgE). At the end of 2017, the FDA approved the registration of Novartis Europharm ' Omalizumab, which will enter the field of an...

Investigation Report on China's Daratumumab Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Daratumumab, developed by Johnson & Johnson, is a monoclonal antibody available for the treatment of myeloma. Its product DARZALEX was approved for the treatment of patients with multiple myeloma who have received at least one therapy, including a pr...

Investigation Report on China's Liraglutide Market 2021-2025
Published in Jun 2021 | US $ 2600 Onwards | By China Research and Intelligence

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, developed by Novo Nordisk A/S. Its product VICTOZA firstly launched in the EU in July 2009 and firstly approved to enter the Chinese market in 2011. Liraglutide is a medication used f...

We are on:

Need Help?

To know about discount offers contact us at [email protected]